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Introduction 
AIDS was first recognised in the United States of 
. America in the late 1970s among homosexual men 
suffering from atypical pneumonia, herpes simplex 
and Kaposi's sarcoma which were associated with 
an  acquired immunodeficiency state. Their 
disease was christened Acquired Immunodeficiency 
Syndrome with the now universally dreaded 
acronym of AIDS'. Within three years of the 
discovery French and American scientists isolated 
a retrovirus, the human immunodeficiency virus type 
1 (HIV -1) as the cause of AIDS. 
AIDS in Africans was encountered about the 
~nidclle of the 1970s and presented as cases of 
atypical pneumonia among affluent Africans from 
sub-Saharan countries who sought consultation in 
European clinics2. The disease is now worldwide 
and is a serious health problem, particularly in 
Africa. AIDS is the leading cause of death among 
adults in Abidjan, Cote d'Ivoire and in Kinshasa and 
among inpatients in Ugandan hospitals. Ninety 
per cent of deaths among child-bearing women in 
Kigali, Rwanda are due to HIV infection2. In 1993, 
when adult HIV infections in the world numbered 
13 million, more than 8 million occurred in 
sub-Saharan African countries. 
The first AIDS epidemic occurred between 1981 and 
1985 when the disease manifested as either 
opportunistic infections or as unusual neoplasms 
such as Kaposi's sarcoma and lymphomas of the 
nervous system. During that period, less than 10 
cases per annum were diagnosed in South Africa. 
Since then, the number of AIDS cases in that part of 
the world rose. It was at the end of that epidemic, 
in 1985 that it was also found that the central 
nervous system (CNS) was more susceptible to AIDS 
than were other parts of the body'a2. It is now known 
that about 50% of patients with AIDS manifest 
disease of the nervous system before they die and 
that 75% of autopsy examinations of victims of AIDS 
reveal involvement of the nervous system3 through 
direct invasion, opportunistic infections or unusual 
neoplasms. 
This paper briefly reviews the neurological and 
neurosurgical manifestations of AIDS as documented 
in Africa at present. It is based on papers 
published or presented on the subject in Africa and 
among Africans and anecdotal experiences from 
various parts of the continent. 
Neurological manifestations 
The spectrum of neurological diseases reported in 
AIDS patients in Africa, like elsewhere in the world, 
is quite wide, ranging from the primary effects of 
HIV o n  the nervous system, to opportunistic 
infections and, rarely, psychiatric disorders. These 
neurological complications may occur before there 
is clinical evidence of immunosuppression and the 
HIV infection is revealed. 
Primary effects of HIV 
HEADACHE 
Case report 
A Malawian 46-year-old male senior police officer 
presented with generalised headache described as 
heaviness of the head. It was continuous, severe 
and associated with episodes of crying with pain. 
He was fully conscious on admission to the Queen 
Elizabeth Central Hospital, Blantyre. He was rest- 
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less with pain but frequent changes of posture did 
not relieve his headache .  There was  n o  
papilloedema. Neurologically there were no 
deficits. Blood pressure was normal. He was ELISA 
positive. 
He was treated with large frequent doses of 
paracetamol-codeine preparations; reassurance; and 
amytriptyline 75mg at night. There was no relief, 
hence  indomethacin was  used  instead of 
paracetamol; finally pethidine was administered. 
Lumbar puncture produced clear cerebrospinal fluid 
(CSF) unde r  normal t o  moderate  pressure.  
Prednisolone was added to his treatment regime. 
His conscious level deteriorated and he died in 
hospital four days after admission. 
Comment 
In managing-HIV related headache in Africa it is 
important to exclude tropical diseases such as 
malaria, syphilis and trypanosomiasis and local 
disorders which can also cause headaches such as 
sinusitis, migraine and dental abscess. The clinical 
assessment should take into consideration diseases 
like aseptic meningitis and intracranial space 
occupying lesions. With more imaging techniques 
becoming available on the continent, management 
of HIV related headaches  should  include 
investigating the patient with CT scan and MRI. 
DEMENTIA COMPLEX 
This is characterised by a wide spectrum of 
pathological disorders and clinical manifestations 
classified from normal (stage 0) to advanced (stage 
4). The early features include personality changes 
with apathy and flat emotion. Next, impaired 
memory and concentration supervene. In the late 
stage the patient manifests ataxia with brisk tendon 
reflexes and Babinski response4. 
In Malawi, two forms of HIV associated dementia 
complex are recognized in the adult: the acute and 
chronic varieties. The acute type is characterised 
by confusion and the chronic one by behavioral 
disorders of apathy, personality changes and 
emotional flatness. The management employed 
consists in attempting to  rule out  treatable 
possibilities l ike malaria, syphilis a n d  
trypanosomiasis. The antiretroviral therapy 
(zidovudine) is not available in many parts of 
Africa. 
In the developing regions of the world, including 
Africa, HIV infected children show delay in 
psychomotor development or the loss of already 
acquired physical and developmental abilities5 
Cognitive defects of speech and memory also 
occur6. CT scan shows brain atrophy and 
ventricular dilatation in these children. 
PERIPHERAL NERVOUS SYSTEM INVOLVEMENT 
It is estimated that about 50% of AIDS patients will 
manifest evidence of peripheral nerve disease in 
the course of their illness'. The various b p e s  
encountered in Africa are helpes zostel; sensory 
painful peripheral neuropathy; isoniazid-related 
neuropathy, Guillain-Barre syndrome and cranial 
nerve palsy. 
Herpes zoster has been found to be  a clinical 
predictor of HIV infection in African patients7. In 
Kinshasa, in Kigali and in Bangui, over 90% of 
patients with heqes zoster were found to be HIV 
p o ~ i t i v e ~ ~ ~ .  The clinical features were similar to 
those found in HIV-negative Africans except that 
recurrences were commoner in HIV patients. 
Whereas helpes zoster is traditionally found in 
patients over 60 years of age and those suffering 
from Hodgkin's disease, HIV-associated herpes zoster 
in Central Africa is a disease of young adults7. 
Axonal sensory painful peripheral neuropathy 
is estimated to affect about 30% of AIDS patients in 
the late stage of their disease. It presents with 
symmetrical intolerable painful paraesthesia and 
numbness in both feet which ascends to the knees. 
Muscle weakness is also associated and foot drop 
may occur'. 
Adam9 from Nairobi, reported the good response 
of this disease to oral prednisolone 40mg daily. He 
reported a series of five women and two men seen 
in Nairobi, Kenya between 1988 and 1992, agecl 
between 45 and 57 years. At presentation, three 
were known to be victims of AIDS and four were 
asymptomatic for HIV infection. One was an 
elderly male who was well except for severe 
burning sensation in his lower limbs and a painful 
band-like pain in the epigastrium referred to his 
lumbar spine. Investigations in general surgery 
and orthopaedic clinics and various endoscopic and 
radiological examinations were normal. He was 
found to be ELISA positive at the Neurology clinic 
and his painful leg was cured within one week of 
prednisolone at a daily dose of 40mg. He responded 
to the same treatment when his pain recurred a 
year later. 
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All the seven patients in the Nairobi study had 
axonal diffuse sensory neuropathy during nerve 
conduction tests. Most of them had treatment with 
tricyclic ant idepressants  (amytriptiline), 
anticonvulsants (phenytoin and carbamazepine), 
fluphenazine, alone or  in various combinations 
without relief before they were  placed o n  
prednisolone. Non-steroidal anti-inflammatory 
drugs did not relieve their pain. The relief of pain 
from steroids was long lasting even after cessation 
of medication. 
Isoniazid-related peripheral neuropathy has 
been seen in Malawi and attention is directed to 
the prevention or  amelioration of the burning 
sensation that occurs in the feet1('. Since it is known 
that, when a TB patient starts isoniazid, his HIV 
associated neuropathy may worsen, all TI3 patients 
should receive pyridoxine 10mg daily as  
prophylaxis against  isoniazid peripheral 
neuropathy. If resources are not buoyant to allow 
this, the pyridoxine prophylaxis should be reserved 
for the HIV-positive patients and TB patients who 
drink alcohol. 
Acute neuropathy of the Guillain Barre type is 
also encoun te red  in HIV-positive African 
patients. In Malawi, it occurs in young adults and 
rarely in children. It may occur at any stage of the 
disease although commonly it is seen at the early 
asymptomatic phase of HIV infection". The 














:ranial neuropathy, single or multiple cranial 
re palsy may occur during asymptomatic or early 
lptomatic HIV infection. In a series of 
arently idiopathic acute peripheral facial palsy 
ifricans reported from Kenya8, eight of the 32 
ents were HIV positive; four of the eight had 
eralized lymphadenopathy; one had herpes zoster 
another had generalized pruritic rash. Two 
.e asymptomatic. The incidence of HIV 
)positivity in patients with acute facial palsy is 
ler in other African countries than the 25% 
xted from Kenya. 
:hronic inflammatory demyelinating 
~ropathy with episodes of clinical recurrences 
Iso seen in the early stages of HIV infection'. 
re is no known documentation of this variety in 
the African. 
Between 10% and 25% of patients with AIDS suffer 
from myelopathy due to direct invasion of the 
thoracic portion of the spinal cord by HIV. The 
clinical manifestations are characteristic enough for 
a presumptive diagnosis to be made in the African. 
These consist of a short history of progressive 
difficulty in walking and the finding on physical 
examination of spastic paraparesis and ataxia, 
impaired vibration and joint position sense and the 
loss of sphincter control. Wadia of Bombay warned 
that peripheral neuropathy may overlap the 
myelopathy to such an extent that the increased 
tendon reflexes of the spastic paraparesis disappears 
but the Babinski response remains. 
In Malawi, the last six cases of HIV myelopathy 
were aged between 25 and 45 years. There were 
four females and two males. The CSF was clear in 
all cases and myelography was normal. In South 
Africa, during a community-based seroprevalence 
survey in Kwazulu Natal 90 cases  of HIV 
myelopathy presenting with spastic paraparesis were 
seenz5 in the neurology unit of Wentworth Hospital 
up to December 1991. HarriesIo has listed the 
various causes of spinal cord disease that must be 
differentiated from HIV myelopathy. These include 
TB spine, schistosomiasis of the cord, cervical 
spondylosis, prolapsed disc, epidural abscess and 
cord tumours like neurofibroma and meningioma. 
There is no specific treatment for HIV myelopathy. 
Its similarity t o  subacute  combined  cord 
degeneration has lead some to treat cases with 
Vitamin B12 injections13. Physiotherapy and 
antispasticity drugs are used to relieve the spastic 
limbs. Baclofen is not always available in parts of 
Africa, necessitating the use of diazepam. The usual 
measures are  taken for treating neurogenic 
bladder. 
Cerebrovascular disease 
AIDS patients appear to have an increased risk of 
cerebral infarction a n d  transient ischaemic 
neurological deficitsI4. These diseases may be the 
initial presentation of AIDS; they often signify the 
presence of treatable CNS infections such as 
opportunistic cerebral lesions, cryptococcal 
meningitis or neuro~yphilis'~. Stroke in the young 
African, aged under 40 years, should evoke the 
suspicion of HIV infection. 
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Meningitis 
This is commoner in HIV infected patients than in 
the general population, the various forms described 
in the literature being tuberculous meningitis (TBM); 
cryptococcal meningitis; acute bacterial; viral; 
syphilitic a n d  the  lymphomatous types1. 
Non-Hodgkin's lymphoma is about 60 times more 
common in AIDS patients than the rest of the 
population, hence the occurrence of lymphomatous 
meningitis. It presents with headaches, mental and 
behavioral changes, convulsions and cranial nerve 
palsies; it responds very well to steroid therapy'. 
The common forms of meningitis reported from HIV 
patients in Africa are the tuberculous, cryptococcal, 
acute bacterial and the viral varieties. In a report 
by Bergemann and Karstaed16 of 284 adult patients 
with HIV associated meningitis admitted to the 
Baragwanath Hospital in Soweto, Johannesburg, 
South Africa, the distribution of the disease was: 
T B M  25.4%, acute bacterial meningitis 22.5%; acute 
viral meningitis 14.1% and cryptococcal meningitis 
13%. Streptococcus pneumoniae  was  the  
commonest organism found in acute bacterial 
meningitis. TBM and cryptococcal meningitis were 
AIDS defining diseases in more than a quarter of 
cases. The authors predicted a rise in the 
incidence of TBM and cryptococcal meningitis in 
Africa. 
Tuberculosis meningitis (TBM) 
The incidence of pulmonary TB and of TBM have 
risen in developing countries due to HIV infection. 
Tuberculosis of the  CNS is usually d u e  to 
Mycobacterfurn tuberculosis and not to the avium 
variety. It occurred in 11% of West Africans with 
tuberculosis and HIV infection in a recent study1'. 
CSF examination typically reveals tubercle bacilli. 
Where CT scan is available, it is advisable to 
perform a head scan first to exclude tuberculoma 
before lumbar puncture to avoid the danger of 
tonsillar herniation. 
The treatment of TBM recommended is the 
four-drug regimen in full dosage comprising 
streptomycin, rifampicin, INAH and pyrazinamide 
for three months. After this treatment, the CSF 
picture usually becomes normal. Rifampicin and 
INAH are then continued for another 12 months. 
TBM and tuberculoma of the brain can coexist. TBM 
can actually develop while a patient is on treatment 
for tuberculosis if a tuberculoma ruptures into the 
brain releasing tubercle bacilli not yet killed by 
anti-TB drugslo. In Central Africa, a few cases of 
TBM complicated by moderate but significant 
hydrocephalus have benefited from ventriculo- 
peritoneal shunting procedure. 
Cryptococcal meningitis 
This is associated with the opportunistic infective 
agent Cyptococcus neoformans, a yeast first 
described in 190518 and which is universally present 
but seems more common in Africa than elsewhere 
in the worlc12. The incidence of cryptococcal 
infection in AIDS patients in the UK is 3.6%; in the 
USA from 2% to 9% and in Africa, as high as 33%I9j2'. 
Cryptococcal meningitis is the third most common 
neurological presentation of AIDS after HIV 
invasion and toxoplasmosislR. It is most common 
in sub-Saharan Africa, occurring in from 6% to 12% 
of AIDS patients2', the increased incidence being 
due to the more common occurrence of the yeast 
or an increased genetic susceptibility of the African 
to cryptococcal infection22. 
Maher and M ~ a n d u m b a ~ ~  reported a series of 31 
cases  from Malawi out  of 30,000 medical 
admissions in an l&month period. Headache, neck 
stiffness, fever and altered consciousness were the 
presenting features In Zaire, serum cryptococcal 
antigen testing helped to predict a group of 
apparently healthy patients who are likely to 
develop cryptococcal meningitis2I but this was not 
so in the UK18. The test was 95% to 100% 
positive for diagnosis in Central Africa where the 
specific drug treatment used was amphotericin B 
and fluconazole. The latter drug is not always 
available in hospitals in Africa; and not more than 
10% of patients can afford to buy it. Under such 
circumstances treatment is symptomatic, consisting 
of the use of analgesia and sedation. 
The prognosis of cryptococcal meningitis in Africa 
is poor, as shown by the report from Malawi. 
Without using the specific anti-cryptococcal 
chemotherapy, the mean survival time from time of 
diagnosis was four days. With treatment, it was 
some months. The problem of this meningitis is 
likely to increase in Africa as HIV infection becomes 
more ~ i d e s p r e a d ~ ~ .  
Neurosurgical aspects 
Levy a n d  Berger2" of the Department  of 
Neurosurgery in Chicago reported that HIV 
infection can manifest as intracranial sepsis, cerebral 
I-- Neuro10,qical and neumsurgical mnnfestations qf HIV 5.3 
mass lesions or as vascular disorders. The same 
experience is shared by neuroscientists at the King 
Edward Hospital, Kwazulu Natal, South Africa3'. 
Intracranial sepsis and HW 
The presentation of intracranial suppurative disease 
is different in HIV positive patients. Multiple brain 
abscesses and suppuration caused by multiple, 
mixed organisms are common in HIV-positive 
patients but are unusual in HIV-negative patients. 
The rest of the differences noted are shown in table 
I.  
TABLE I Brain abscess : experience in a South African 
hospital (Bhigjegl 1996) 
Cerebral mass lesions 
Ten per cent of HIV-positive patients in Durban 
had mass lesions comprising toxoplasmosis, 
lymphoma and PML. 
I toxc 





Toxoplasma encephalitis, caused by the protozoan 
Toxoplasma gondii is the most treatable CNS 
complication of AIDS. It results from reactivation 
of latent disease and occurs in the advanced stage 
of HIV infection when the CD4 count is below 100. 
It is seen in about 3% to 10% of AIDS patients in the 
rTs4 but here, in Africa, where seroprevalence of 
)plasma is high, it has been predicted the 
3ence maybe as high as 50%26. Whereas only 
I of AIDS patients from Africa treated in Europe 
le years ago had toxoplasma encephalitis', a 




re are three main features of the disease. 
ieralised neurological symptoms develop over 
:w days to weeks characterised by severe 
claches and altered mental status. Secondly, 
icute encephalitis may develop. Thirdly, there 
t. focal findings which result from involvement of 
e Frontal and parietal lobes and the basal ganglia. 
volvement of the basal ganglia causes movement 
disorders of cerebellar ataxia and chorea. The 
latter, in AIDS patients,  is almost always 
pathognomonic of toxoplasma encephalitis2'. 
Diagnosis of toxoplasma encephalitis is definitively 
and best made by stereotaxic brain biopsy. Lack 
of facilities for the procedure in many places in 
Africa or  reluctance o n  the  part of the 
neurosurgeon to do the biopsy, have led to the use 
of therapeutic diagnostic trial. The practice in 
Africa is to begin treatment on a presumptive 
diagnosis. In Durban, oral clindamycin and 
pyrimethamine therapy provide rapid clinical and 
radiographic improvement with 72% of patients 
responding on day seven of treatment. Steroids are 
to be avoided. 
CT scan and MRI show multiple contrast enhancing 
lesions. These are not diagnostic of toxoplasma as 
they may mimic tuberculoma o r  lymphoma. 
Serum antibody test for toxoplasma is often 
positive. 
Lymphoma 
Primary lymphoma of the CNS is seen in about 3% 
of AIDS patients,  Half of the  cases 
present clinically and the other half are picked up 
at This incidence is similar to the 
experience in Africa2". 
Progressive multifocal leukoencephalopathy 
(PML) 
PML, due to reactivation of the JC virus, is seen in 
about 5% of patients. The clinical features 
depend on the site of demyelination. 
Unrelated neurosurgical disease 
HIV seropositivity may occur coincidentally with 
any neurosurgical disorder, notably in those with 
neurotrauma and with intracranial vascular anomaly. 
HIV positivity worsens the prognosis of these 
neurosurgical diseases. 
Discussion 
The incidence of CNS involvement in patients with 
HIV infection in Africa is not known for sure due to 
the paucity of reports on the subject. Given the 
widespread nature of HIV infection in Africa, it may 
be higher than the 79% and 85% incidence recently 
reported from Indiaz9 and France3' respectively. 
Like elsewhere in the worldz9, cryptococcal 
meningitis and toxoplasma encephalitis are 
invariably fatal in Africa. Lack of financial resources 
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to obtain appropriate but expensive chemotherapy 
contributes to the high mortality. The early deaths 
from opportunistic infection may explain the 
relative infrequency of CNS lymphomas in AIDS 
patients in Africa. 
While the pathogenesis of the primary effects of 
HIV on the nervous system is unclear, experiences 
from Africa have  establ ished some  valid 
information about HIV invasion of the peripheral 
nervous system. Thus reports from Central Africa 
have shown herpes zoster to be a clinical predictor 
of HIV infecti~n' ,~ and, in Kenya, prednisolone has 
been shown to be consistently superior to tricyclic 
antidepressants, anticonwlsants and non-steroidal 
anti-inflammatory drugs in the relief of axonal 
sensory peripheral neuropathy9. 
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